Female Health Co. (NASDAQ:FHCO)

CAPS Rating: 5 out of 5

The Female Health Company engages in the manufacture, marketing, and distribution of the female condom.

Results 1 - 20 of 58 : 1 2 3 Next »

Recs

0
Member Avatar Reddragyn (69.84) Submitted: 4/12/2014 6:17:56 PM : Outperform Start Price: $7.49 FHCO Score: -0.82

CAPS5

Recs

0
Member Avatar roguer (< 20) Submitted: 3/10/2014 10:22:34 AM : Outperform Start Price: $7.10 FHCO Score: +7.24

sell the female condom. distributed abroad. massive free cash flow.

Recs

2
Member Avatar ValuePicksOnly (86.53) Submitted: 2/12/2014 2:39:03 AM : Outperform Start Price: $6.73 FHCO Score: +10.19

The price of FHCO is in decline since their last earnings release. What people seem to forget, and what FHCO management is constantly repeating, is that their income fluctuates immensely due to the spending patterns of governments and NGO's. Despite lower reported earnings there is NO decrease in demand, it is just the cycle.

I therefore see this as an amazing opportunity to make us of irrational behavior by investors. This company has a tremendously strong balance sheet. My intrinsic value estimate is $12.

Recs

0
Member Avatar shrutisDad (59.46) Submitted: 12/6/2013 3:13:28 PM : Outperform Start Price: $8.99 FHCO Score: -18.88

Under-valued, near-monopoly

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/6/2013 7:35:50 PM : Outperform Start Price: $8.75 FHCO Score: -23.66

Long. 14x fye. 21% rev growth. Female condoms.

Recs

0
Member Avatar mainiac5800 (< 20) Submitted: 5/25/2013 8:43:32 PM : Outperform Start Price: $8.86 FHCO Score: -26.17

Management owns a big slice of the pie, here. They keep voting themselves new dividends. Sales of female condoms are increasing in the developing world.

Recs

0
Member Avatar leglamp (58.10) Submitted: 4/23/2013 7:33:53 PM : Outperform Start Price: $7.34 FHCO Score: -14.96

This company has a great yield, low P/E and is solving a global problem.

Recs

0
Member Avatar BGPenhollo (46.29) Submitted: 4/3/2013 8:32:42 PM : Outperform Start Price: $7.14 FHCO Score: -13.85

Low debt, unique and needed product, unbelievable ROI. reasonable to low PE, and it pays a dividend with a payout of less than 50%. It's a no-brainer for me.

Recs

1
Member Avatar AlexeiVronsky (81.89) Submitted: 3/23/2013 12:32:00 AM : Outperform Start Price: $6.54 FHCO Score: -3.66

Seems to be a fundamentally sound company, though the reliance on government and NGO income means I won't be adding it to my portfolio.

Recs

1
Member Avatar BKITU (96.96) Submitted: 3/12/2013 11:31:31 AM : Outperform Start Price: $6.64 FHCO Score: -5.91

Decent financials, consumable product, lots of growth potential not only in industrializing countries, but in already-industrialized countries. That's a rare treat these days.

Recs

0
Member Avatar FutureMonkey (84.11) Submitted: 3/2/2013 2:53:31 PM : Outperform Start Price: $6.97 FHCO Score: -14.24

Top 25 best company pick

Recs

0
Member Avatar s123entler (< 20) Submitted: 3/1/2013 1:28:46 PM : Outperform Start Price: $6.96 FHCO Score: -13.85

There is a defintie need for theior producct which will continue for quite a while.

Recs

0
Member Avatar AStarSearch (63.73) Submitted: 2/11/2013 10:50:55 PM : Outperform Start Price: $7.21 FHCO Score: -21.83

underdeveloped nations need this

Recs

0
Member Avatar mitleg (< 20) Submitted: 1/12/2013 4:58:28 PM : Outperform Start Price: $7.21 FHCO Score: -21.83

This has been a steady performer, bit it is still cheap. It also helps to have a product that is revolutionary.

Recs

0
Member Avatar WakeUpInvestor (43.80) Submitted: 1/4/2013 7:10:55 PM : Outperform Start Price: $7.07 FHCO Score: -20.74

During the London Summit in 2012, the Female Health Company announced a program to support the London Summit's goal to provide contraceptives to an additional 120 million women by 2020. This program includes a plan for the company to invest up to $14 million over the next six years in reproductive health and HIV/AIDS prevention education and training in collaboration with global agencies.

Recs

1
Member Avatar aufergy (88.83) Submitted: 11/16/2012 3:21:32 PM : Outperform Start Price: $6.10 FHCO Score: -12.82

I just bought this in real life. The reasons I bought are:
- Debt free balance sheet
- Company has strong margins and produces healthy free cash flow. They even produced FCF in 2011 when their sales were way down due to some big orders that were delayed until 2012.
- Very little (if any) competition. They have the only FDA approved product.
- They have US and UK tax-loss carry forwards that will benefit net income.
- Demand is increasing and they just completed an expansion of their production facility.

A company that has a nice moat in a niche that should continue to grow, a strong balance sheet, and only one analyst following it. All that for 16x trailing earnings? I'm in. Peter Lynch would be proud.

Recs

0
Member Avatar Pickle57 (52.68) Submitted: 10/17/2012 1:28:21 AM : Outperform Start Price: $7.66 FHCO Score: -29.14

It's a World Health Organization play. Not to worry about fundamentals, rather big public funding to spread their product around the 3rd world.

Recs

0
Member Avatar WilliamCrook2003 (71.47) Submitted: 9/8/2012 12:30:51 PM : Outperform Start Price: $6.65 FHCO Score: -15.41

A fun stock to have when the time is right!!

Recs

0
Member Avatar 2008Rehab (22.33) Submitted: 9/8/2012 9:26:35 AM : Outperform Start Price: $6.65 FHCO Score: -15.41

Nice concept.

Recs

0
Member Avatar maazzoo69 (89.47) Submitted: 8/1/2012 12:36:39 AM : Outperform Start Price: $5.92 FHCO Score: -6.62

Population growth but with moderation as compared to the past because having children is becoming a more important financial matter in everyday family.

Results 1 - 20 of 58 : 1 2 3 Next »

Featured Broker Partners


Advertisement